ArticleDigestive diseases and sciences2026
Development and Validation of a Crotonylation-Related Prognostic Risk Model for Cholangiocarcinoma Based on Integrative Transcriptome Analysis.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundCholangiocarcinoma (CCA) is a common and highly refractory malignancy; however, biomarkers and therapeutic targets associated with its progression remain incompletely understood. Crotonylation is an emerging lysine acylation modification that has been implicated in multiple diseases.
aimsIn this study, we aimed to identify crotonylation-related prognostic genes in CCA.
methodsFirst, differentially expressed genes (DEGs) with consistent expression patterns were identified using the TCGA-CHOL and GSE26566 datasets. Key module genes associated with the expression patterns of known lysine crotonylation-related gene (LCRG) scores were subsequently identified through weighted gene co-expression network analysis (WGCNA), and candidate genes were obtained by intersection analysis.
resultsThree prognostic genes, complement factor H (CFH), phosphatidylcholine N-methyltransferase (PEMT), and tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon (YWHAE), were ultimately selected to construct and validate a prognostic risk model. In addition, immune infiltration analysis revealed significant differences in mast cell abundance between the high- and low-risk groups. Moreover, the expression levels of the immune checkpoints FMS-like tyrosine kinase 3 (FLT3) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) also differed between the two risk groups.
conclusionsThese findings may have important implications for CCA immunotherapy and provide a theoretical basis for improving diagnostic and prognostic assessment in CCA.
Indexed as
Identifiers
42400718What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.